Biopharmaceutical Company Issues Restructuring Proceedings Update

VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company driven by immunology in its pursuit of powerful prevention and treatment of diseases, has recently provided an update on its restructuring proceedings. This update follows the company's announcement on July 30, 2024, regarding their entry into restructuring proceedings due to financial and operational difficulties. $VBI Vaccines (VBIV.US)$